Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses Market

The article provides an in-depth analysis of the global market for non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses. It discusses the expected consumption trends, market performance, and value projections up to 2030. Key findings include the top consuming and producing countries, fluctuations in consumption and production volumes, and a detailed breakdown of global exports and imports. The analysis highlights the growth potential and challenges in the market, offering valuable insights for stakeholders in the pharmaceutical and healthcare industries.

Market Forecast

Driven by increasing demand for non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses worldwide, the market is expected to continue an upward consumption trend over the next eight-year period. Market performance is forecast to decelerate, expanding with an anticipated CAGR of +2.9% for the period from 2022 to 2030, which is projected to bring the market volume to 1.9M tons by the end of 2030.

In value terms, the market is forecast to increase with an anticipated CAGR of +5.1% for the period from 2022 to 2030, which is projected to bring the market value to $104.3B (in nominal prices) by the end of 2030.

Consumption

World Consumption of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses

In 2022, approx. 1.5M tons of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses were consumed worldwide; approximately reflecting the previous year. Over the period under review, the total consumption indicated a strong increase from 2012 to 2022: its volume increased at an average annual rate of +6.5% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, consumption increased by +71.9% against 2016 indices. Over the period under review, global consumption of attained the maximum volume at 1.5M tons in 2021, and then shrank in the following year.

The value of the market for non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses worldwide declined modestly to $70B in 2022, with a decrease of -3.2% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). Overall, consumption, however, enjoyed prominent growth. Over the period under review, the global market reached the peak level at $72.2B in 2021, and then fell modestly in the following year.

Consumption By Country

The countries with the highest volumes of consumption in 2022 were Israel (314K tons), China (259K tons) and the United States (127K tons), together comprising 46% of global consumption. India, Japan, Indonesia, Pakistan, Russia, Canada, Bangladesh, the UK, Germany and Italy lagged somewhat behind, together accounting for a further 28%.

From 2012 to 2022, the biggest increases were recorded for Canada (with a CAGR of +13.0%), while uses for the other global leaders experienced more modest paces of growth.

In value terms, Japan ($28.9B) led the market, alone. The second position in the ranking was held by the United States ($8.7B). It was followed by Russia.

From 2012 to 2022, the average annual growth rate of value in Japan totaled +9.0%. In the other countries, the average annual rates were as follows: the United States (+7.7% per year) and Russia (+4.4% per year).

In 2022, the highest levels of per capita consumption of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses was registered in Israel (33 kg per person), followed by Canada (0.9 kg per person), Japan (0.5 kg per person) and Italy (0.4 kg per person), while the world average per capita consumption of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses was estimated at 0.2 kg per person.

In Israel, per capita consumption of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses increased at an average annual rate of +6.8% over the period from 2012-2022. In the other countries, the average annual rates were as follows: Canada (+11.7% per year) and Japan (+5.8% per year).

Production

World Production of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses

Global production of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses fell slightly to 1.6M tons in 2022, approximately mirroring the previous year's figure. The total output volume increased at an average annual rate of +4.2% from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The growth pace was the most rapid in 2019 with an increase of 33%. Global production peaked at 1.6M tons in 2021, and then dropped slightly in the following year.

In value terms, production of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses dropped slightly to $69.9B in 2022 estimated in export price. In general, production, however, saw prominent growth. The pace of growth appeared the most rapid in 2019 with an increase of 36% against the previous year. Global production peaked at $72.6B in 2021, and then contracted slightly in the following year.

Production By Country

The countries with the highest volumes of production in 2022 were Israel (356K tons), China (281K tons) and the United States (122K tons), together accounting for 49% of global production.

From 2012 to 2022, the most notable rate of growth in terms of uses, amongst the leading producing countries, was attained by China (with a CAGR of +10.0%), while uses for the other global leaders experienced more modest paces of growth.

Imports

World Imports of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses

In 2022, overseas purchases of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses were finally on the rise to reach 170K tons for the first time since 2018, thus ending a three-year declining trend. In general, imports continue to indicate a relatively flat trend pattern. Global imports peaked at 175K tons in 2018; however, from 2019 to 2022, imports failed to regain momentum.

In value terms, imports of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses surged to $9B in 2022. Overall, imports saw a relatively flat trend pattern. The growth pace was the most rapid in 2018 when imports increased by 45% against the previous year. As a result, imports reached the peak of $15.1B. From 2019 to 2022, the growth of global imports of failed to regain momentum.

Imports By Country

In 2022, Australia (23K tons), followed by Canada (15K tons), the United States (14K tons) and France (11K tons) were the main importers of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses, together making up 37% of total imports. Spain (7.4K tons), India (6.7K tons), the UK (6.2K tons), China (5.7K tons), the Netherlands (3.9K tons), Brazil (3.8K tons), Argentina (3.7K tons), South Korea (3.5K tons) and Germany (3.2K tons) followed a long way behind the leaders.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the main importing countries, was attained by China (with a CAGR of +24.4%), while imports for the other global leaders experienced more modest paces of growth.

In value terms, the UK ($1.3B), the United States ($1.1B) and Canada ($1.1B) appeared to be the countries with the highest levels of imports in 2022, with a combined 38% share of global imports.

In terms of the main importing countries, Canada, with a CAGR of +33.3%, recorded the highest rates of growth with regard to the value of imports, over the period under review, while purchases for the other global leaders experienced more modest paces of growth.

Import Prices By Country

In 2022, the average import price for non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses amounted to $52,957 per ton, growing by 9% against the previous year. In general, the import price, however, showed a relatively flat trend pattern. The pace of growth appeared the most rapid in 2018 an increase of 26% against the previous year. As a result, import price reached the peak level of $85,972 per ton. From 2019 to 2022, the average import prices remained at a somewhat lower figure.

There were significant differences in the average prices amongst the major importing countries. In 2022, amid the top importers, the country with the highest price was the UK ($201,817 per ton), while Australia ($2,180 per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Germany (+14.6%), while the other global leaders experienced more modest paces of growth.

Exports

World Exports of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses

In 2022, approx. 221K tons of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses were exported worldwide; with an increase of 18% against the previous year's figure. Over the period under review, exports, however, continue to indicate a drastic downturn. The most prominent rate of growth was recorded in 2016 with an increase of 23% against the previous year. The global exports peaked at 573K tons in 2017; however, from 2018 to 2022, the exports failed to regain momentum.

In value terms, exports of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses skyrocketed to $8.5B in 2022. Overall, total exports indicated a mild expansion from 2012 to 2022: its value increased at an average annual rate of +1.1% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, exports decreased by -36.2% against 2018 indices. The pace of growth appeared the most rapid in 2020 with an increase of 37% against the previous year. The global exports peaked at $13.4B in 2018; however, from 2019 to 2022, the exports stood at a somewhat lower figure.

Exports By Country

In 2022, Israel (43K tons), distantly followed by China (28K tons), India (25K tons), Singapore (20K tons), Jordan (16K tons) and Canada (11K tons) were the largest exporters of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses, together committing 65% of total exports. Spain (9.6K tons), the United States (9K tons), Belgium (7.7K tons), South Africa (7.6K tons), France (6.8K tons), Egypt (5K tons) and the Netherlands (4.3K tons) held a relatively small share of total exports.

From 2012 to 2022, the biggest increases were recorded for Singapore (with a CAGR of +20.2%), while shipments for the other global leaders experienced more modest paces of growth.

In value terms, Israel ($1.4B), the United States ($1B) and Spain ($604M) constituted the countries with the highest levels of exports in 2022, together accounting for 36% of global exports. China, Singapore, India, the Netherlands, France, Belgium, Jordan, Canada, South Africa and Egypt lagged somewhat behind, together accounting for a further 27%.

Singapore, with a CAGR of +18.6%, recorded the highest growth rate of the value of exports, in terms of the main exporting countries over the period under review, while shipments for the other global leaders experienced more modest paces of growth.

Export Prices By Country

The average export price for non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses stood at $38,511 per ton in 2022, rising by 6.7% against the previous year. Overall, the export price enjoyed a remarkable increase. The growth pace was the most rapid in 2018 an increase of 155% against the previous year. As a result, the export price attained the peak level of $51,018 per ton. From 2019 to 2022, the average export prices remained at a somewhat lower figure.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was the United States ($111,244 per ton), while Egypt ($1,206 per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by the United States (+13.6%), while the other global leaders experienced more modest paces of growth.

Source: IndexBox Market Intelligence Platform